Research programme: glucocorticoid receptor II antagonists - Corcept TherapeuticsAlternative Names: CORT 112716; CORT 113083; CORT 118335; CORT 122928; CORT 125281
Latest Information Update: 07 Feb 2017
At a glance
- Originator Corcept Therapeutics
- Mechanism of Action Glucocorticoid receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alcoholism; Alzheimer's disease; Amyotrophic lateral sclerosis; Cancer; Memory disorders; Metabolic disorders; Muscular dystrophies; Non-alcoholic fatty liver disease; Obesity; Post-traumatic stress disorders; Prostate cancer; Psychiatric disorders